Indication
Transthyretin Amyloidosis
8 clinical trials
9 products
Product
PatisiranClinical trial
HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)Status: Active (not recruiting), Estimated PCD: 2020-11-10
Product
VutrisiranClinical trial
An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) With Disease Progression Post-Orthotopic Liver TransplantStatus: Completed, Estimated PCD: 2020-10-06
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)Status: Completed, Estimated PCD: 2023-05-11
Product
PlaceboProduct
acoramidisClinical trial
Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran TherapyStatus: Recruiting, Estimated PCD: 2024-10-01
Product
patisiranClinical trial
An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart TransplantationStatus: Recruiting, Estimated PCD: 2025-04-30
Product
TafamidisClinical trial
A Follow-Up Study to Monitor Therapeutic Response in Transthyretin Cardiac Amyloidosis Using Amyloid Reactive Peptide 124I-evuzamitide (AT01) PET/CTStatus: Recruiting, Estimated PCD: 2024-06-01
Product
I 124-EvuzamitideClinical trial
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis: A Community StudyStatus: Recruiting, Estimated PCD: 2024-08-01
Product
99mTc-PYPClinical trial
A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) AmyloidosisStatus: Not yet recruiting, Estimated PCD: 2031-06-27